Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Thursday. $152.20 million flowed into the stock on the tick-up and $116.59 million flowed out of the stock on the tick-down, for a money net flow of $35.61 million into the stock. Of all stocks tracked, Johnson & Johnson had the 10th highest net in-flow for the day. Johnson & Johnson traded down ($0.13) for the day and closed at $122.51

A number of analysts recently weighed in on the stock. Royal Bank Of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, April 17th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, April 17th. BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. Finally, Piper Jaffray Cos. increased their price objective on shares of Johnson & Johnson from $105.00 to $106.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 20th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $112.36.

The company has a 50 day moving average of $116.60 and a 200-day moving average of $108.93. The company has a market capitalization of $337.92 billion and a price-to-earnings ratio of 22.39.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 19th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.03. The company earned $17.50 billion during the quarter, compared to analyst estimates of $17.50 billion. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.56 EPS. Analysts predict that Johnson & Johnson will post $6.61 EPS for the current fiscal year.

In related news, CAO Ronald A. Kapusta sold 3,957 shares of the stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $114.77, for a total transaction of $454,144.89. Following the completion of the sale, the chief accounting officer now owns 29,682 shares in the company, valued at approximately $3,406,603.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Gary J. Pruden sold 9,735 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the sale, the vice president now owns 43,630 shares of the company’s stock, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

Other hedge funds have modified their holdings of the company. Agran Libbie boosted its stake in shares of Johnson & Johnson by 9,867.0% in the fourth quarter. Agran Libbie now owns 10,352,436 shares of the company’s stock worth $10,634,000 after buying an additional 10,248,569 shares in the last quarter. Independent Franchise Partners LLP boosted its stake in shares of Johnson & Johnson by 3.7% in the fourth quarter. Independent Franchise Partners LLP now owns 7,919,329 shares of the company’s stock worth $813,473,000 after buying an additional 284,002 shares in the last quarter. Russell Frank Co boosted its stake in shares of Johnson & Johnson by 11.9% in the fourth quarter. Russell Frank Co now owns 6,787,317 shares of the company’s stock worth $704,483,000 after buying an additional 722,085 shares in the last quarter. Eaton Vance Management boosted its stake in shares of Johnson & Johnson by 50.4% in the fourth quarter. Eaton Vance Management now owns 6,595,870 shares of the company’s stock worth $677,528,000 after buying an additional 2,211,218 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Johnson & Johnson by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,975,223 shares of the company’s stock worth $613,820,000 after buying an additional 275,499 shares in the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.